Chief Commercial Officer · ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

James Hassard

A named executive officer of ARROWHEAD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$784,808

Salary $431,673Stock awards $0

FY2020: $7,918,296

5th of 6 named executive officers at Arrowhead Pharmaceuticals by FY2021 total.

6 named officers on file for ARROWHEAD PHARMACEUTICALS, FY2021

James Hassard’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • ARWR’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARROWHEAD PHARMACEUTICALS’s whole pay program stands against its peers

  • ARROWHEAD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARWR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 26, 2022 (DEF 14A).

Free

Get James Hassard’s full pay file as a PDF — free

More than this page: up to 10 years of James’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

James Hassard compensation by year

ARROWHEAD PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as ARROWHEAD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$302,404$431,673
Bonus$0$0
Stock awards$7,430,000$0
Option awards$0$0
Non-equity incentive$170,000$0
Pension and deferred compensation$0$0
All other$15,892$353,135
Total$7,918,296$784,808

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARROWHEAD PHARMACEUTICALS, INC. DEF 14A filed January 26, 2022, accession 0001193125-22-018280, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARROWHEAD PHARMACEUTICALS, INC. filed document, accession 0001193125-22-018280. Every figure is read from that document and cited to the page and table it appears in. Filed January 26, 2022.

$7.9M
$785K
FY20
FY21
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU125,000$5,382,500—

Per the Outstanding Equity Awards at Fiscal Year-End table in ARROWHEAD PHARMACEUTICALS, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

ARROWHEAD PHARMACEUTICALS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Christopher AnzalonePresident and Chief Executive Officer$24,703,855
Patrick O'BrienChief Operating Officer and General Counsel$5,336,926
Kenneth MyszkowskiChief Financial Officer$5,333,570
James HamiltonVP Discovery and Translational Medicine$4,509,947
James Hassard · this pageChief Commercial Officer$784,808
Javier MartinChief Medical Officer$658,480

The full ARROWHEAD PHARMACEUTICALS compensation record

free company brief

This page is one person within ARROWHEAD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARROWHEAD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARROWHEAD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Hassard's compensation dossier · One-time report. No refunds.